Dossier assessment

Lisocabtagene maraleucel (DLBCL, HGBCL, PMBCL and FL3B, each after one prior therapy) – Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A23-48
Last updated

Report documents

  1. Extract of dossier assessment

    Lisocabtagene maraleucel (DLBCL, HGBCL, PMBCL and FL3B, each after one prior therapy) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 785 kB, EN, not accessible
  2. Dossier assessment

    Lisocabtagene maraleucel (DLBCL, HGBCL, PMBCL and FL3B, each after one prior therapy) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 2 MB, DE, not accessible

Dossier assessment

Indication:

Adults with diffuse large B-cell lymphoma, high grade B-cell lymphoma, primary mediastinal large B-cell lymphoma or follicular lymphoma grade 3B, who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy

Result of dossier assessment:
  • Patients < 65 years who are eligible for high-dose therapy: hint of a non-quantifiable added benefit
  • Patients ≥ 65 years who are eligible for high-dose therapy: added benefit not proven
  • Patients with diffuse large B-cell lymphoma or high grade B-cell lymphoma who are not eligible for high-dose therapy: added benefit not proven
  • Patients with primary mediastinal large B-cell lymphoma or follicular lymphoma grade 3B who are not eligible for high-dose therapy: added benefit not proven

Press releases

Lisocabtagene maraleucel in second-line for B-cell lymphoma: added benefit for certain patients

Based on the available data, there is a hint of a non-quantifiable added benefit for patients under 65 years of age who are eligible for high-dose therapy.

Additional information

Federal Joint Committee (G-BA)

2023-11-17 A G-BA decision was published.

G-BA documents on this decision

Project details

Project no.
A23-48
Commission
Commission awarded on 31.05.2023 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Cancer
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

Connected Projects

  1. Dossier assessment

    Lisocabtagene maraleucel (DLBCL, PMBCL and FL3B) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A22-90
    Last updated

    Status: Commission completed

  2. Addendum

    Lisocabtagene maraleucel (DLBCL, HGBL, PMBCL and FL3B, second line) – Addendum to Commission A23-48

    Project no.
    A23-98
    Last updated

    Status: Commission completed

  3. Dossier assessment

    Lisocabtagene maraleucel (follicular lymphoma) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A25-47
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form